retatrutide phase 2 trial results Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished retatrutide phase 2 obesity trial

Your gut naturally produces GLP-1, the un-hunger hormone that plays multiple roles in metabolic health

Most people eventually stop taking a GLP-1 estimates reach as high as 92% which means medication alone is not enough

However, the ongoing treatment costs for these medications raise concerns about the sustainability of their widespread use in the healthcare system, especially given the risk of weight regain without continued use

Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment

[7] [8] Personal importation of unlicensed medicinal products is not a safe or lawful route to obtain medicines and may result in the product being seized by UK Border Force

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis